Osiris Therapeutics

Osiris Therapeutics, Inc. was founded in 1992 based on stem cell technology discovered by researchers at Case Western Reserve University led by Dr. Arnold Caplan. He recognized this technology had tremendous therapeutic potential.
Today, more than two decades after the journey began, Osiris continues to advance the science of cellular regenerative medicine to treat patients in need. Osiris Therapeutics, based in Columbia, Maryland, is the world leader in researching, developing and marketing regenerative medicine products. Having developed the world’s first approved stem cell drug, the company continues to advance its research and development in biotechnology by focusing on innovation in regenerative medicine – including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in orthopaedics, sports medicine and wound care, including BIO4™, Cartiform® and Grafix®. Osiris, Grafix, and Cartiform are registered trademarks of Osiris Therapeutics, Inc. BIO4 is a trademark of Stryker Corporation (NYSE: SYK).

Type
Public
HQ
Columbia, US
Founded
1992
Size (employees)
211 (est)
Website
osiris.com
Osiris Therapeutics was founded in 1992 and is headquartered in Columbia, US

Key People/Management at Osiris Therapeutics

Linda Palczuk

Linda Palczuk

President and CEO
Philip R. Jacoby

Philip R. Jacoby

CFO

Osiris Therapeutics Office Locations

Osiris Therapeutics has an office in Columbia
Columbia, US (HQ)
7015 Albert Einstein Drive

Osiris Therapeutics Financials and Metrics

Osiris Therapeutics Financials

USD

Net income (FY, 2014)

(1.8 m)

EBIT (FY, 2014)

1.7 m

Market capitalization (31-Oct-2017)

172.3 m

Closing share price (31-Oct-2017)

4.7

Cash (31-Dec-2014)

2.2 m
Osiris Therapeutics's current market capitalization is $172.3 m.
USDFY, 2013FY, 2014

EBIT

(2.8 m)1.7 m

Net Income

41.6 m(1.8 m)
USDFY, 2013FY, 2014

Cash

2.4 m2.2 m

Accounts Receivable

15.3 m10 m

Inventories

355 k650 k

Current Assets

84.1 m95.9 m
USDFY, 2013FY, 2014

Depreciation and Amortization

587 k940 k

Accounts Receivable

(4.7 m)(18 m)

Inventories

(651 k)(9 m)

Accounts Payable

(2.8 m)(57 k)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015

Accounts Receivable

6.8 m15.1 m256 k474 k7.6 m720 k562 k

Inventories

1.7 m2.3 m5.5 m8.8 m11.9 m13.3 m15.8 m

Accounts Payable

4 m8 m9.3 m9.8 m9.2 m9.6 m
Show all financial metrics

Osiris Therapeutics Market Value History

Osiris Therapeutics's Web-traffic and Trends

Osiris Therapeutics Company Life and Culture

You may also be interested in